VA Begins Nationwide Trial Testing Semaglutide as a Potential Treatment for Alcohol Use Disorder in Veterans
New Research Examines Whether a GLP-1 Medication Could Help Reduce Problem Drinking
The U.S. Department of Veterans Affairs (VA) has launched a major nationwide clinical trial to investigate whether semaglutide, a medication commonly used for diabetes and weight management, could help veterans struggling with alcohol use disorder (AUD).
The study represents one of the most significant efforts in years to explore a new medical approach for treating problematic drinking. Researchers hope the trial will determine whether semaglutide can reduce alcohol consumption, improve health outcomes, and provide veterans with another treatment option.
Alcohol use disorder is a serious medical condition that affects a person’s ability to control drinking despite negative consequences. According to the VA, more than 400,000 veterans have been diagnosed with AUD. Estimates also suggest that the condition affects nearly 11% of adults in the United States.
Despite how common AUD is, treatment options have changed very little over the past two decades. The U.S. Food and Drug Administration (FDA) has not approved a new medication specifically for alcohol use disorder in nearly 20 years.
Why Researchers Are Studying Semaglutide for Alcohol Use Disorder
Semaglutide belongs to a group of medications called GLP-1 receptor agonists. These drugs were originally developed to help manage type 2 diabetes by improving blood sugar control. They have also become widely known for their role in weight management treatments.
Scientists became interested in semaglutide and similar GLP-1 medications because these drugs may influence areas of the brain involved in reward, motivation, and cravings.
Alcohol and other addictive substances affect the brain’s reward pathways. Researchers believe that medications affecting these systems could potentially reduce the urge to drink or change how rewarding alcohol feels.
Recent research has added to this interest. A study published in the British Medical Journal found that people taking GLP-1 medications had lower rates of alcohol use disorder and other substance use disorders compared with people taking other diabetes medications.
The VA has also reported that individuals with substance use disorders who use GLP-1 medications have experienced fewer emergency department visits and hospitalizations. While these findings are promising, researchers emphasize that a controlled clinical trial is necessary to determine whether semaglutide can directly help treat AUD.
The CRAVE Clinical Trial
The new VA study is called the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial.
The research will include more than 600 veterans between the ages of 18 and 80 who have moderate to severe alcohol use disorder. Participants will be recruited from 18 VA medical centers across the country, including locations ranging from Seattle to Orlando, Florida.
During the trial, participants will receive weekly injections of either semaglutide or a placebo for approximately 24 weeks. After the treatment period, researchers will continue monitoring participants for safety.
The study team will examine several factors, including:
- Changes in alcohol consumption
- Overall physical health
- Quality of life improvements
- Safety and side effects
- Whether semaglutide provides meaningful benefits compared with placebo treatment
The goal is to determine whether semaglutide could become a useful addition to current alcohol use disorder treatments.
Current Challenges in Treating Alcohol Use Disorder
Although medications are available for AUD, many people do not receive medical treatment.
The most commonly prescribed medication, oral naltrexone, can help some people reduce alcohol cravings and drinking. However, its effectiveness is considered modest, and many individuals with AUD do not receive any medication treatment.
According to the ClinicalTrials.gov listing for the CRAVE study, fewer than 2% of adults with alcohol use disorder take medication for the condition in a given year.
The treatment gap is also seen among veterans. Although the VA supports medication-based treatment as a recommended approach, only about 40,000 of the more than 400,000 veterans diagnosed with AUD are actively receiving medication treatment.
Researchers hope studies like CRAVE can help expand available options and make treatment more accessible for veterans and others affected by alcohol use disorder.
Why This Trial Matters for Veterans
Veterans may face unique challenges related to alcohol use, including stress, trauma exposure, physical health concerns, and difficulties adjusting after military service.
Finding additional treatment options could help healthcare providers offer more personalized care based on individual needs.
VA Secretary Doug Collins said the trial reflects the VA’s ability to conduct large-scale medical research focused on improving veteran health.
“By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery,” Collins said in a VA news release.
The trial could also provide valuable information for the broader medical community. If semaglutide shows positive results, future research may examine whether GLP-1 medications could help other groups affected by alcohol use disorder.
What Happens Next?
Recruitment for the CRAVE trial began on July 28, 2026. Veterans interested in participating can contact their local VA medical center or review enrollment information through ClinicalTrials.gov.
The results of the study will determine whether semaglutide is a safe and effective treatment option for reducing alcohol consumption among veterans with AUD.
Until clinical trial results are available, healthcare professionals caution that semaglutide should not be considered an established treatment for alcohol use disorder. More research is needed before doctors can determine its long-term role in addiction care.
Conclusion
The VA’s nationwide semaglutide trial represents an important step in exploring new approaches for alcohol use disorder treatment. After years with limited medication advances, researchers are examining whether a drug already used for diabetes and weight management could provide additional support for people struggling with problematic drinking.
For veterans living with AUD, new treatment possibilities could offer hope for improved recovery options. The CRAVE trial will provide critical evidence about whether semaglutide can become part of the future of alcohol use disorder care.
Sources
- U.S. Department of Veterans Affairs. “VA Launches Nationwide Clinical Trial Exploring GLP-1 Medication for Alcohol Use Disorder.” July 30, 2026.
- ClinicalTrials.gov. “Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) Trial.” July 23, 2026.
- British Medical Journal. Research examining associations between GLP-1 medications and reduced rates of alcohol and substance use disorders.
Disclaimer
This article is for informational and educational purposes only and is not medical advice. Semaglutide is not currently approved by the FDA as a treatment for alcohol use disorder. Anyone experiencing concerns related to alcohol use should speak with a qualified healthcare professional about available treatment options.